PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of ...

Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

The S&P 500 came off lows as President Trump delayed Mexico tariffs, but the market's initial reaction highlights the ...

Major employers and innovators recognised at ceremony showcasing Ireland’s pharmaceutical leadership, as sector marks record ...

We argue against selling Geron at current prices, citing strong market potential of imetelstat and Royalty Pharma deal valuation. Read more on GERN stock here.

Welcoming Gabrielle to the role, Simon McKeever, Chief Executive of the IEA, said: “We are delighted that Gabrielle will ...